Genmab Licenses MIF Receptor Target from Cytokine PharmaSciences

Genmab A/S and Cytokine PharmaSciences Inc. have announced that Genmab has licensed rights to the MIF receptor target from Cytokine PharmaSciences. Genmab intends to develop therapeutic human antibodies to the licensed target

Genmab A/S is a biotechnology company creating and developing human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing.

For further information please contact:

Helle Husted,

Director Investor Relations

Tel: +45 33 44 77 30

Email: hth@genmab.com

Or visit: www.genmab.com

Home > News & Events > News > Genmab Licenses MIF Receptor Target from Cytokine PharmaSciences
Last updated: 2006-12-22

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

GENMAB A/S

GENMAB A/S

Genmab A/S (CSE: GEN) is a global biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions,...